Xiaorong W. Mao

P.R. China
Lanzhou, 730000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Withaferin A, a candidate drug for lupus nephritis, confers renal protection via Pon1‑mediated attenuation of oxidative stress.

Withaferin A, a candidate drug for lupus nephritis, confers renal protection via Pon1‑mediated attenuation of oxidative stress.

Journal: International journal of molecular medicine

Published: January 09, 2026

A Novel Deep Learning Framework for Liver Fibrosis Staging and Etiology Diagnosis Using Integrated Liver-Spleen Elastography.

A Novel Deep Learning Framework for Liver Fibrosis Staging and Etiology Diagnosis Using Integrated Liver-Spleen Elastography.

Journal: Diagnostics (Basel, Switzerland)

Published: October 28, 2025

Annexin A5 ameliorates immune-mediated liver injury by regulating ferritinophagy-ferroptosis in M2 macrophages via the NRF2/ERK pathway.

Annexin A5 ameliorates immune-mediated liver injury by regulating ferritinophagy-ferroptosis in M2 macrophages via the NRF2/ERK pathway.

Journal: Cellular signalling

Published: August 31, 2025

Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study.

Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study.

Journal: Virology journal

Published: August 03, 2025

Targeting GCS regulates the NRF2 axis to inhibit hepatocyte endoplasmic reticulum stress-ferroptosis improving immune-mediated liver injury.

Targeting GCS regulates the NRF2 axis to inhibit hepatocyte endoplasmic reticulum stress-ferroptosis improving immune-mediated liver injury.

Journal: International immunopharmacology

Published: May 10, 2025

Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.

Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.

Journal: Gut

Published: April 15, 2025

Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-Suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China.

Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-Suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 19, 2025

Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study.

Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study.

Journal: Hepatology (Baltimore, Md.)

Published: February 18, 2025

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: December 16, 2024

Case Report: Infection with Streptococcus constellatus manifesting as gelatinous pleural effusion in an HIV-positive patient.

Case Report: Infection with Streptococcus constellatus manifesting as gelatinous pleural effusion in an HIV-positive patient.

Journal: Frontiers in immunology

Published: December 14, 2024

Annexin A: Cell Death, Inflammation, and Translational Medicine.

Annexin A: Cell Death, Inflammation, and Translational Medicine.

Journal: Journal of inflammation research

Published: December 10, 2024

Disulfiram in liver diseases: a double-edged sword.

Disulfiram in liver diseases: a double-edged sword.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: October 28, 2024

Showing 1-12 of 35

Last Updated: 09/26/2026